Health-related quality of life in secondary progressive multiple sclerosis

Author:

Beiske A.G.1,Naess H.2,Aarseth J.H.3,Andersen O.3,Elovaara I.4,Farkkila M.5,Hansen H.J.6,Mellgren S.I.7,Sandberg-Wollheim M.8,Sorensen P.S.9,Myhr K.M.10

Affiliation:

1. Department of Neurology, University Hospital of Akershus, Lørenskog, Norway

2. Department of Neurology, Haukeland University Hospital, Bergen, Norway

3. Institute of Clinical Neuroscience, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden

4. Neuroimmunology Unit, Department of Neurology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland

5. Department of Neurology, Helsinki University, Helsinki, Finland

6. Department of Neurology, Aarhus Hospital, Aarhus University Hospital, Aarhus, Denmark

7. Department of Neurology, University Hospital of North Norway, Tromsö, Norway

8. Department of Neurology, University Hospital, University of Lund, Lund, Sweden

9. Danish MS Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

10. Department of Clinical Medicine, Section of Neurology, University of Bergen, Bergen, Norway

Abstract

Common disability scales in multiple sclerosis (MS) are often weighted towards physical disability. Non-motor symptoms such as depression, fatigue and pain substantially influence wellbeing in MS. Health-related quality of life (HRQoL) measures the broader impact of MS and might indicate less obvious disease burdens. We analysed HRQoL, using the Nottingham Health Profile Part I (NHP-I), among 345 secondary progressive MS (SPMS) patients participating in a randomized trial of interferon-β1a (IFN-β1a), 22 μg subcutaneously weekly, or matching placebo. The results did not reveal any beneficial effect of IFN-β1a in any outcome measure. NHP-I sub- and sum scores were compared for 217 population controls and correlated with demographic and clinical disease variables. SPMS patients had lower NHP-I sum and all subscores than the controls. Patients experiencing disease progression reported worse NHP-I sum scores. Increased fatigue, Expanded Disability Status Scale (EDSS) and Arm Index scores were independently associated with reduction in several NHP-I subscores. SPMS patients had significantly lower HRQoL than controls and physical disability (EDSS and Arm Index), disease progression and fatigue strongly influenced this. MS

Publisher

SAGE Publications

Subject

Clinical Neurology,Neurology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3